Bone marrow cells injected into salivary glands to fight dry mouth

NCT ID NCT06392711

Recruiting now Symptom relief Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether injecting mesenchymal stromal cells (MSCs) into the salivary glands is safe and can ease dry mouth in people with graft-versus-host disease or Sjogren's disease. Up to 36 adults will receive one injection and be monitored for pain and side effects. The study is primarily checking safety, but will also track changes in dry mouth symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mesenchymal stromal cells (MSCs)
What this could lead to: If it works, this could point toward a new way to treat chronic dry mouth without radiation.
What could go wrong: This is a very early, small phase 1 trial focused on safety, not proof of effectiveness. The approach may not improve symptoms and could cause pain or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT-VERSUS-HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

graft versus host disease Sjogren syndrome Xerostomia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT-VERSUS-HOST DISEASE SJOGREN'S DISEASE XEROSTOMIA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

University of Wisconsin
RECRUITING

Madison, Wisconsin, 53705, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.